Literature DB >> 31656794

Are we facing a cure in lung cancer?-KEYNOTE-001 insights.

Aharon Y Cohen1, Waleed Kian1, Laila C Roisman1, Dina Levitas1, Nir Peled1, Yulia Dudnik1.   

Abstract

Entities:  

Year:  2019        PMID： 31656794      PMCID： PMC6789365          DOI： 10.21037/atm.2019.08.87

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  13 in total

1.  Pembrolizumab plus Chemotherapy in Lung Cancer.

Authors:  Omer Diker
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

4.  Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

Authors:  Martin Reck; Michael Schenker; Ki Hyeong Lee; Mariano Provencio; Makoto Nishio; Krzysztof Lesniewski-Kmak; Randeep Sangha; Samreen Ahmed; Judith Raimbourg; Kynan Feeney; Romain Corre; Fabio Andre Franke; Eduardo Richardet; John R Penrod; Yong Yuan; Faith E Nathan; Prabhu Bhagavatheeswaran; Michael DeRosa; Fiona Taylor; Rachael Lawrance; Julie Brahmer
Journal:  Eur J Cancer       Date:  2019-06-11       Impact factor: 9.162

5.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

6.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 9.  Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.

Authors:  Yang Liu; Yinping Dong; Li Kong; Fang Shi; Hui Zhu; Jinming Yu
Journal:  J Hematol Oncol       Date:  2018-08-16       Impact factor: 17.388

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245
View more
  3 in total

1.  Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001.

Authors:  Wisdom Akingbemi; Edward Garon
Journal:  Ann Transl Med       Date:  2020-06

2.  The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation.

Authors:  Hanno M Witte; Bastian Bonorden; Armin Riecke; Harald Biersack; Konrad Steinestel; Hartmut Merz; Alfred C Feller; Veronica Bernard; Sebastian Fetscher; Nikolas von Bubnoff; Niklas Gebauer
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

3.  Magnitude, temporal trends and inequality in global burden of tracheal, bronchus and lung cancer: findings from the Global Burden of Disease Study 2017.

Authors:  Zhaojun Wang; Liu Hu; Junhang Zhang; Jun Zhou; Jin Li; Li Wei
Journal:  BMJ Glob Health       Date:  2020-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.